Schizophrenia | Unmet Need | Schizophrenia (Positive Symptoms) | US/EU | 2016

The positive symptoms of schizophrenia (e.g., hallucinations, delusions) are a symptom domain of schizophrenia that affects approximately 83% of the 3.2 million diagnosed prevalent cases of schizophrenia in the markets under study (i.e., United States, United Kingdom, France, and Germany). Despite the availability of 32 atypical and typical antipsychotic therapies, which are considered the standard of care for resolving the positive symptoms of schizophrenia, the majority of drug-treated patients experience symptom relapse or inadequate symptom remittance because of these therapies’ insufficient efficacy and/or intolerability (which can result in treatment discontinuation). Thus, within this mature and rapidly genericizing market, commercial opportunities exist for emerging therapies that improve upon current antipsychotics’ tolerability and/or efficacy.

Login to access report

launch Related Market Assessment Reports